

Date: May 21, 2026

To

The Manager

Listing Compliance Department

National Stock Exchange of India Ltd.

Exchange Plaza, Bandra Kurla Complex,

Bandra (E), Mumbai-400051, India

Corporate Office :

406, Silver Oaks Comm. Complex,

Opp. Arun Society, Paldi,

Ahmedabad-380 007. Gujarat, India.

Phone : 079-26584655

CIN No. : L24231GJ2004PLC043861

E-mail : info@sakarhealthcare.com

Web : www.sakarhealthcare.com

SUB: Sakar enters it's 40th agreement signed with Zydus Lifesciences to cater oncology products to GCC and other emerging markets, in parallel to building momentum on strong execution and expanding Business Opportunities

Dear All,

Sakar Healthcare Ltd continues to make steady progress in its strategic initiatives, reflecting strong business momentum and positioning the company for sustained long-term growth. To share a business update:

- Sakar Healthcare Ltd has signed an agreement with Zydus Lifesciences for supplying oncology products in the GCC (Gulf Cooperation Council) & other emerging markets. With this Sakar marks the 40th agreement with anti-cancer products, globally.
- The company has made 23 Marketing Authorization (MA) filings in the European Union (EU), of which
 - 5 MAs have been secured of 8 filed by partner in Bulgaria, rest have been applied in Czech Republic, Croatia & Poland
 - Sakar has applied for 13 own MAs in EU
- Company has progressed in regulatory filings with 33 site variations submitted including Accord Healthcare Limited (UK), Heumann Pharma GmbH & Co. Generica KG-Germany, Torrent Pharma-UK, Tillomed Laboratories Ltd.-UK, with 18 cytotoxic molecules across the EU covering Germany, Italy, Norway, France, Finland, Sweden, Malta, Romania & the UK; with at present 5 site variation approvals- 3 by EMA (EU) and 2 by the MHRA (UK). This reinforces Sakar's growing execution capabilities in complex, regulated markets.
- On the API side, Sakar's integration strategy is gaining traction, with 21 APIs developed in-house, including 16 with Written Confirmation and 2 CEP approvals already secured. With additional CEP approvals under review, the company is seeing increasing validation of its capabilities in high-entry-barrier markets.
- These developments mark a clear transition towards a more integrated, regulatory-led business model, enhancing supply chain control, margin visibility, and scalability.
- With a strengthening pipeline of approvals and increasing integration across the value chain, Sakar is well-positioned to accelerate growth, expand market share, and drive the next leg of earnings.

Commenting on the development, Mr. Sanjay Shah, Managing Director, Sakar Healthcare Ltd, said: *"These achievements underscore our focus on backward integration, strengthening regulatory capabilities, and expanding across global markets. We are encouraged by the progress in our regulatory approvals and API pipeline, supported by multiple approvals and a strong set of applications under review. This strengthens our ability to scale operations, enhance market share, and deliver meaningful revenue growth in the coming years."*

Thanking You,

FOR, SAKAR HEALTHCARE LIMITED

BHARAT SONI

COMPANY SECRETARY

